How many insider trades does FilingIQ track for LPCN?

FilingIQ tracks 71 Form 4 insider transactions for LPCN (Lipocine Inc.), covering filings from Oct 2, 2015 onwards. 3 of those are dated within the last 90 days.

Are LPCN insiders net buyers or net sellers?

Across the full Form 4 history for LPCN, 31 transactions (44%) were open-market purchases and 14 (20%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.

Where does LPCN insider data come from?

Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ normalises insider identity across reporting variations and scores discretionary open-market purchases and sales on its multi-factor composite model.

What sector is LPCN in?

Lipocine Inc. (LPCN) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $49.91M.

LPCN insider trading

NasdaqCM Healthcare

Lipocine Inc.: insider trade history from SEC Form 4 filings.

Total Form 4 trades

Last 90 days

Buys / sells

44% / 20%

Market cap

$49.91M

About Lipocine Inc.

Lipocine Inc., a clinical-stage biopharmaceutical company, engages in the research and development for the delivery of drugs for the treatment of central nervous system (CNS) disorders. Its lead product candidate is TLANDO, an oral testosterone replacement therapy (TRT) comprising testosterone undecanoate. The company's pipeline candidates also include LPCN 1111 (TLANDO XR), a next-generation long-acting oral product candidate for TRT; LPCN 1148, a novel prodrug of testosterone and testosterone laurate for the treatment of cirrhosis; LPCN 1154 to treat postpartum depression; LPCN 2101, a NAS candidate for women with epilepsy; and LPCN 2203, an oral candidate for management of essential tremor. It also develops LPCN 1144, an oral prodrug of bioidentical testosterone for the treatment of metabolic dysfunction-associated steatohepatitis; LPCN 2401 to improve body composition in obesity management; and LPCN 1107, an oral hydroxy progesterone caproate product indicated for the prevention of recurrent preterm birth. The company was founded in 1997 and is headquartered in Salt Lake City, Utah.

Company website: www.lipocine.com

LPCN insider activity at a glance

FilingIQ tracks 71 insider transactions for LPCN in filings since Oct 2, 2015. The most recent transaction is dated Sep 30, 2026.

Across the full history, 31 open-market purchases and 14 open-market sales were filed under transaction codes P and S respectively. Compensatory share awards (code A) and option exercises (code M) are tracked separately and not counted here.

The average FilingIQ composite score on LPCN insider trades is 63.0/100, produced by FilingIQ's multi-factor Form 4 model. Model framework documented at methodology.

View live LPCN trades on FilingIQ Raw filings on SEC EDGAR

Latest LPCN Form 4 filings

Patel Mahesh V. Chief Executive Officer

Patel Mahesh V. Chief Executive Officer

P Apr 6, 2026

Most recent disclosures. Sign up to filter by score, transaction code, or insider role.

Other Healthcare tickers with recent insider activity

UTHR 820

UNITED THERAPEUTICS Corp

THERMO FISHER SCIENTIFIC INC.

NTRA 129

Natera, Inc.

ATTO 123

Attovia Therapeutics, Inc.

CORT 110

CORCEPT THERAPEUTICS INC

TEM 104

Tempus AI, Inc.

Frequently asked

How many insider trades does FilingIQ track for LPCN?: FilingIQ tracks 71 Form 4 insider transactions for LPCN (Lipocine Inc.), covering filings from Oct 2, 2015 onwards. 3 of those are dated within the last 90 days.
Are LPCN insiders net buyers or net sellers?: Across the full Form 4 history for LPCN, 31 transactions (44%) were open-market purchases and 14 (20%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
Where does LPCN insider data come from?: Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ normalises insider identity across reporting variations and scores discretionary open-market purchases and sales on its multi-factor composite model.
What sector is LPCN in?: Lipocine Inc. (LPCN) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $49.91M.

Methodology & sources

Every LPCN insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.